帕尼单抗（维克替比）。
Panitumumab (vectibix).
机构信息
Department of Radiology, Division of Neuroradiology, University of Michigan Health System, Ann Arbor, 48109, USA.
出版信息
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):1002-3. doi: 10.3174/ajnr.A2601. Epub 2011 May 19.
Abstract
Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody.
摘要
帕尼单抗（Vectibix）是人源化单克隆抗体 EGFR 拮抗剂，与氟嘧啶、奥沙利铂和伊立替康化疗方案治疗后疾病进展的转移性结直肠癌的单药治疗。本文将介绍该单克隆抗体的作用机制和临床作用。
相似文献
1
Panitumumab (vectibix).帕尼单抗（维克替比）。
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):1002-3. doi: 10.3174/ajnr.A2601. Epub 2011 May 19.
2
Panitumumab: a review of its use in metastatic colorectal cancer.帕尼单抗：在转移性结直肠癌中的应用评价。
Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000.
3
FDA drug approval summary: panitumumab (Vectibix).美国食品药品监督管理局药物批准摘要：帕尼单抗（维克替比）。
Oncologist. 2007 May;12(5):577-83. doi: 10.1634/theoncologist.12-5-577.
4
Spotlight on panitumumab in metastatic colorectal cancer.重点关注转移性结直肠癌的 panitumumab。
BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000.
5
Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.帕尼单抗：转移性结直肠癌治疗中靶向治疗的新前沿。
Expert Rev Anticancer Ther. 2010 Apr;10(4):499-505. doi: 10.1586/era.10.28.
6
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.用于治疗转移性结直肠癌的表皮生长因子受体单克隆抗体
Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.
7
Immunogenicity of panitumumab in combination chemotherapy clinical trials.帕尼单抗在联合化疗临床试验中的免疫原性。
BMC Clin Pharmacol. 2011 Nov 9;11:17. doi: 10.1186/1472-6904-11-17.
8
[Panitumumab].帕尼单抗
Med Monatsschr Pharm. 2008 Apr;31(4):122-6.
9
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.美国食品药品监督管理局对帕尼单抗（维克替比）用于转移性结直肠癌一线治疗的一项临床试验的审评。
Oncologist. 2009 Mar;14(3):284-90. doi: 10.1634/theoncologist.2008-0254. Epub 2009 Mar 12.
10
Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.帕尼单抗：一种对转移性结直肠癌有活性的全人源单克隆抗体。
Ann Pharmacother. 2007 Apr;41(4):606-13. doi: 10.1345/aph.1H492. Epub 2007 Mar 13.
引用本文的文献
1
Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions.结直肠癌靶向治疗与化疗策略的进展：当前见解与未来方向
Biomedicines. 2025 Mar 5;13(3):642. doi: 10.3390/biomedicines13030642.
2
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment.索托拉西布联合帕尼单抗联合疗法在结直肠癌治疗中的新作用。
Int J Clin Oncol. 2025 May;30(5):867-877. doi: 10.1007/s10147-025-02736-y. Epub 2025 Mar 13.
3
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations.抗表皮生长因子受体适配体对携带表皮生长因子受体L858R突变的非小细胞肺癌细胞具有直接抗癌作用。
NPJ Precis Oncol. 2024 Nov 21;8(1):271. doi: 10.1038/s41698-024-00758-9.
4
Immuno-PET Imaging of EGFR with Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts.EGFR 免疫 PET 显像：应用 Cu-NOTA 帕尼单抗在皮下和转移性非小细胞肺癌异种移植瘤中的研究
Mol Pharm. 2024 Nov 4;21(11):5797-5806. doi: 10.1021/acs.molpharmaceut.4c00823. Epub 2024 Oct 15.
5
Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift.创新型纳米颗粒策略在结肠癌治疗中的应用：范式转变。
AAPS PharmSciTech. 2024 Mar 1;25(3):52. doi: 10.1208/s12249-024-02759-0.
6
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.表皮生长因子受体抑制剂在脑胶质瘤中的应用：现状与未来可能。
Int J Mol Sci. 2024 Feb 15;25(4):2316. doi: 10.3390/ijms25042316.
7
Enhancing treatment strategies for small bowel cancer: a clinical review of targeted therapy and immunotherapy approaches.增强小肠癌治疗策略：靶向治疗和免疫治疗方法的临床综述。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):4601-4614. doi: 10.1007/s00210-024-02992-1. Epub 2024 Feb 8.
8
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.靶向癌症中人类表皮生长因子受体家族的抗体药物偶联物
Front Mol Biosci. 2022 Feb 28;9:847835. doi: 10.3389/fmolb.2022.847835. eCollection 2022.
9
Oxidative Stress in Cancer Cell Metabolism.癌细胞代谢中的氧化应激
Antioxidants (Basel). 2021 Apr 22;10(5):642. doi: 10.3390/antiox10050642.
10
How to select IgG subclasses in developing anti-tumor therapeutic antibodies.如何在开发抗肿瘤治疗性抗体中选择 IgG 亚类。
J Hematol Oncol. 2020 May 5;13(1):45. doi: 10.1186/s13045-020-00876-4.
本文引用的文献
1
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.帕尼单抗：其用于治疗转移性结直肠癌的证据
Core Evid. 2010 Oct 21;5:61-76. doi: 10.2147/ce.s7035.
2
Spotlight on panitumumab in metastatic colorectal cancer.重点关注转移性结直肠癌的 panitumumab。
BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000.
3
Panitumumab: a review of its use in metastatic colorectal cancer.帕尼单抗：在转移性结直肠癌中的应用评价。
Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000.
4
Panitumumab.帕尼单抗
Br J Clin Pharmacol. 2009 Oct;68(4):482-3. doi: 10.1111/j.1365-2125.2009.03492.x.
5
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.癌症治疗中的抗表皮生长因子受体单克隆抗体
Clin Exp Immunol. 2009 Oct;158(1):1-9. doi: 10.1111/j.1365-2249.2009.03992.x.
6
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.用人抗表皮生长因子受体单克隆抗体靶向治疗结直肠癌：聚焦帕尼单抗
Biologics. 2008 Jun;2(2):223-8. doi: 10.2147/btt.s1980.
7
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.针对表皮生长因子受体抗体的结直肠癌治疗：以 panitumumab 为重点。
Ther Clin Risk Manag. 2008 Dec;4(6):1221-7. doi: 10.2147/tcrm.s4314.
8
Targeted therapies: a new generation of cancer treatments.靶向治疗：新一代癌症治疗方法。
Am Fam Physician. 2008 Feb 1;77(3):311-9.
9
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.表皮生长因子受体作为结直肠癌的治疗靶点
Clin Colorectal Cancer. 2003 Feb;2(4):246-51. doi: 10.3816/CCC.2003.n.006.
Zotero 插件